Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy. - Wikidata - wikimedia - TriplyDB

Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.

Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.

http://www.wikidata.org/entity/Q34509012

about

Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes.Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010.Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection Prevalence, Risk Factors, and Pathophysiology of Dysglycemia among People Living with HIV in Sub-Saharan Africa In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus

P2860

Q26768147-47199F02-20E7-422B-8C96-2A6F94E0F5A4 Q28079826-1C629063-15C7-4C72-BB9E-C767C758184C Q33916655-F7FAF8B8-939A-4701-A6FE-2B759D9891D1 Q35860942-F45B183B-F39B-49F0-8364-4077692ADCB1 Q35992200-8F2732BB-9F32-4176-BAD9-4A9DDA7D6541 Q36327164-995295C6-41A9-414C-8287-574593334351 Q36654972-582042CE-A179-4EEF-BE96-C1689D5AAD9C Q37627175-3FFDBD62-3F6F-4CBC-948B-D06F96CFFDCC Q40692524-E4C2F00F-1B16-4D8D-BEB6-CD69A2EEBA99 Q56978971-C83632F1-20ED-4557-BE4A-B710DC6138B9 Q57822378-790D9249-2733-4C71-98EA-7E05A83727B0

P2860

Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.

http://www.wikidata.org/entity/Q34509012

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@ast

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@en

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@nl

type

label

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@ast

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@en

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@nl

prefLabel

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@ast

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@en

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@nl

P1433

Q34509012-221C4775-FB92-4834-9AE2-07A3F12D9672

P1476

Q34509012-43FC0F9C-9EBB-46DB-8B17-D2DBB212D2C2

P2093

Q34509012-03EF92EB-CCF5-40C7-9769-9AA5913F992A

Q34509012-17DE9FB8-0AF7-499B-A151-B922F4E707E2

Q34509012-1E196A0E-E00E-45C9-8B96-EE7F9C372F55

Q34509012-A607B91C-BE6F-465C-87B2-5A296FF280B2

Q34509012-AACE39F3-1173-4DC1-A8A8-7F4C36D3C1B9

Q34509012-BDA25DF0-38A5-446E-B141-B6613B186557

Q34509012-D2E6DFF4-8D91-43B9-BABA-5DDD47F07AE1

Q34509012-F51ADBDA-A83E-47B8-9FBB-A43C05553244

P2860

Q34509012-01D708D0-E95B-469F-8CAB-EC43983E1461

Q34509012-05EFEAEF-A15A-4A73-A1CA-9D96F00CF9F9

Q34509012-0EBE8F23-AC0E-4FAF-8625-06843AC68CBA

Q34509012-1E300868-AE2B-4706-863B-8B2FB1EC4457

Q34509012-277E9D87-0FBD-4ACB-B1E6-BAB1F2C03E08

Q34509012-27A208EA-5628-440A-9B52-029B809160D4

Q34509012-2B23E17A-A59B-43E3-90E2-9ABB257FAC60

Q34509012-2FB90956-4CAD-44F8-AFDE-8B5852368118

Q34509012-3888B7FB-4936-4C14-9747-B18297F1ECCB

Q34509012-4751808F-B10B-49B7-8911-20F889A7416E

P304

Q34509012-74E9F8C6-55B8-4BE2-B792-F7BC723096B6

P31

Q34509012-5EF5524D-E8A5-4F79-AC45-31C1F0E2F409

P356

Q34509012-F2A45F38-57AE-4533-BC4F-16EA7E60DD5E

P407

Q34509012-9E266620-5677-4E27-B474-B0FD3E04E5BD

P433

Q34509012-57C4429E-FC08-4D9D-9A90-73DB50884EA7

P478

Q34509012-732AFA1B-7858-488B-BE4B-8FD4536E09C4

P50

Q34509012-75C04DE3-29AC-40F0-8AC3-F8CD6729F337

Q34509012-C296F989-E7B0-48FC-8464-9F87A61B8A90

P577

Q34509012-7C9C21E8-6A5E-4734-BE14-69844F69F157

P698

Q34509012-DA5A6FFF-158E-49D2-86C7-1261A968F448

P921

Q34509012-3DE7E3BA-322A-468D-BC5E-66AF1D27B370

Q34509012-92AA67CE-44E3-4119-8B6B-6034DDFA4C2A

P932

Q34509012-DC2E377D-1DE2-40BB-A3F0-E9E8AF1FE0B5

P356

QAI.0000000000000354

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Interleukin-6, high sensitivit ...... taking antiretroviral therapy.

@en

P2093

Adrian Palfreeman

http://www.w3.org/2001/XMLSchema#string

Claude Béténé A Dooko

http://www.w3.org/2001/XMLSchema#string

ESPRIT Study Groups

http://www.w3.org/2001/XMLSchema#string

INSIGHT SMART

http://www.w3.org/2001/XMLSchema#string

Jacqueline Neuhaus

http://www.w3.org/2001/XMLSchema#string

James D Neaton

http://www.w3.org/2001/XMLSchema#string

Rosalie Pepe

http://www.w3.org/2001/XMLSchema#string

Stephane De Wit

http://www.w3.org/2001/XMLSchema#string

P2860

Active Smoking and the Risk of Type 2 Diabetes

Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

Type 2 diabetes as an inflammatory disease

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

CD4+ count-guided interruption of antiretroviral treatment

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).

P304

538-546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000354

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

James S. Pankow

Stéphane De Wit

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25393940

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

antiretroviral drug

P932

4231540

http://www.w3.org/2001/XMLSchema#string